2024-03-28T20:10:45Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00028287
2023-01-16T04:20:51Z
499:500:501
Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis
Asai, Shuji
92256
Nagai, Kaoru
92257
Takahashi, Nobunori
92258
Watanabe, Tatsuo
92259
Matsumoto, Takuya
92260
Asai, Nobuyuki
92261
Sobue, Yasumori
92262
Ishiguro, Naoki
92263
Kojima, Toshihisa
92264
gastrointestinal symptoms
methotrexate
patient‐reported outcomes
quality of life
rheumatoid arthritis
Aim: This study aimed to determine the influence of methotrexate (MTX) on gastrointestinal (GI) symptoms in patients with rheumatoid arthritis (RA). Methods: This cross‐sectional study examined 529 consecutive patients with RA receiving oral MTX in our department between April 1 and September 30, 2017. GI symptoms were evaluated by the Gastrointestinal Symptom Rating Scale (GSRS); a score of ≥2 was considered “symptomatic.” Prevalence of GI symptoms was compared between patients receiving ≤8 mg/wk (low‐dose) vs >8 mg/wk (high‐dose) of MTX. Results: Of our study population, 313 (59%) received low‐dose MTX at a median (interquartile range) dose of 6 (6‐8) mg/wk, whereas 216 (41%) received high‐dose MTX at a median dose of 12 (10‐12) mg/wk. Relative to the low‐dose MTX group, the high‐dose MTX group exhibited a higher prevalence of reflux (32% vs 24%, P = 0.043) and abdominal pain (28% vs 18%, P = 0.007). There was no significant group‐dependent difference in the prevalence of indigestion, diarrhea or constipation. Multivariate logistic regression analysis revealed that high‐dose MTX (>8 mg/wk) was independently associated with reflux (odds ratio [OR]: 1.62, 95% confidence interval [CI]: 1.07‐2.43) and abdominal pain (OR: 1.60, 95% CI: 1.04‐2.43), and that the ORs for reflux and abdominal pain among those receiving high‐dose MTX (>8 mg/wk) were similar to those using nonsteroidal anti‐inflammatory drugs. Conclusion: High‐dose MTX is independently associated with the prevalence of upper GI symptoms in Japanese patients with RA.
ファイル公開:2020-02-01
journal article
Wiley
2019-02
application/pdf
International Journal of Rheumatic Diseases
2
22
207
213
1756-1841
https://nagoya.repo.nii.ac.jp/record/28287/files/IJRD_R1_Manuscript_clean_180718.pdf
eng
https://doi.org/10.1111/1756-185X.13380
This is the peer reviewed version of the following article: [Asai, S, Nagai, K, Takahashi, N, et al. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis. 2019; 22: 207– 213. https://doi.org/10.1111/apl.13380], which has been published in final form at [https://doi.org/10.1111/1756-185X.13380]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.